The Impact of the Drug Quality and Security Act on Compounding Pharmacies Is the Subject of May 13th Seminar in Boston
AGAWAM, MASS. — April 29, 2014 — A seminar focusing on the impact of HR3204 — the Drug Quality and Security Act — on compound pharmacies and manufacturers is the subject of a seminar set for May 13, 2014 in Dedham, Mass., near Boston.
Meeting the new guidelines will require substantial changes for many compounders. The seminar is designed to explain the stepping stones needed to comply with the new legislation as well as review USP <797> in its current state.
The seminar will provide pharmacies and compounders that do business as compounding manufacturers and outsourcing facilities with the knowledge they need to know about how the new regulatory expectations will affect their businesses.
Seminar topics will include:
· Becoming a compounding manufacturer
· Manufacturing under cGMP requirements
· Meeting current USP <797> requirements
The seminar will be presented by Microtest Laboratories, a leader in testing services for the medical device, pharmaceutical, and biotechnology industries, on Tuesday, May 13, 2014, from 9 a.m. to 3 p.m. at the Endicott House in Dedham, Mass., just outside Boston. Registration is at 8:30 a.m. A continental breakfast, break refreshments, and a luncheon are included.
To register, visit http://www.microtestlabs.com/seminar or contact Julie Adamski 1-800-631-1680, ext. 192, or jadamski@microtestlabs.com. Advance registration is $149.
quoted from here
No comments:
Post a Comment